CClinicalTrials.gg
Status unknownNCT05027100Updated Jul 1, 2022

Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

An interventional study of Anlotinib Tislelizumab Irinotecan in Small Cell Lung Cancer (SCLC), sponsored by Haibo Zhang. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Haibo Zhang · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high. The strategy for local limited SCLC patients was chemotherapy plus chest radiotherapy; In patients with extensive stage SCLC, first-line platinum-based chemotherapy has been established as the standard treatment for patients with small cell lung cancer (SCLC) with better results. Although the initial response to chemotherapy is high, it is easy to relapse and develop drug resistance.

In second-line therapy, the single-agent activity of multiple chemotherapy agents has been demonstrated, but a higher incidence of grade 3-4 hematological adverse events In the Passion study published by Wang Jie et al. [10], the efficacy and safety of the antiangiogenic drug apatinib combined with carrizumab in the second-line treatment of small cell lung cancer were investigated. A total of 59 patients were enrolled in the study. Of the 47 patients in the extended phase, the confirmed ORR was 34.0% (95%CI 20.9-49.3), with a median PFS of 3.6 months and a median OS of 8.4 months In patients with platinum sensitivity and platinum resistance, ORR was 37.5% vs 32.3%, MPFS was 3.6m vs 2.7m, and MOS was 9.6m vs 8.0m. Grade 3 treatment-related adverse events (TRAEs) occurred in 43 of the 59 patients (72.9%), and 5 patients (8.5%) were discontinued due to TRAEs. The combination regimen showed potential antitumor activity in both platinum-sensitive and platinum-resistant cases.

The research and exploration of small cell lung cancer can learn from the research idea in the field of non-small cell lung cancer. The Checkmate9LA study reported in 2020ASCO [11] investigated the safety and efficacy of Nivolumab+2 cycle chemotherapy in first-line treatment of non-small cell lung cancer with negative driver gene. The MOS in the immunization combination group was significantly better than that in the chemotherapy group (15.6 months vs. 10.9 months, HR 0.66), and the 1-year survival rate was 63% vs. 47%, respectively. The ORR in the immunization combination group was also improved (38% vs. 25%), and the MDOR was 11.3m vs. 5.6m, which was tolerable in terms of safety. The incidence of grade 3-4 treatment-associated AE was 47% in the immune-combined group and 38% in the chemotherapy group. From the perspective of mechanism, chemotherapy can enhance the immunogenicity of tumor cells, damage the immune cell inhibitory activity, which can induce tumor cell apoptosis, expression of MHC class 1 molecules increases and mature dendritic cells to promote the immune response, in the design, add 2 cycles of chemotherapy short-term intensive treatment, make up the immune short board, For example, the early onset of slow and immune characteristic events such as large tumor load, pseudo progression, hyperrogression and other problems, to achieve the optimization and upgrading of the scheme.

Based on Rationale 307, Tislelizumab was approved on January 12, 2021 for first-line treatment in combination with paclitaxel and carboplatin in patients with locally advanced or metastatic squamous non-small cell lung cancer. t the same time, Tislelizumab initial efficacy in patients with extensive small-cell lung cancr.Rational-206 study is a phase Ⅱ multi-cohort study of Tislelizumab combined with first-line platinum-containing chemotherapy in patients with advanced lung cancer in China. The MPFS in the SCLC cohort was about 7 months, and the MOS reached 15.6 months.

Based on the above studies and data, in the second-line treatment of SCLC, anti-vascular targeted drugs combined with chemotherapy can obtain a certain survival benefit, especially for patients with sensitive recurrence, and the benefit is more significant. he immune checkpoint inhibitors have gradually emerged in the second-line and later treatment of SCLC, but the single drug effect has not been a great breakthrough; a small molecule antiangiogenic targeted drug in China, Anlotinib has obtained third-line and later indications of SCLC through ALTER1202 data, and has been included in the 2019 CSCO Guidelines for the Diagnosis and Treatment of Primary Lung Cancer. t the same time, it is similar to the Checkmate9LA study regimen, combined with two cycles of chemotherapy, to improve the short-term efficacy. Therefore, Anlotinib combined with Tislelizumab, a PD-1 inhibitor, and 2 cycles of Irinotecan monotherapy were tried in second-line SCLC, with the hope of breaking through the difficulties of high recurrence rate and rapid disease progression of existing second-line SCLC chemotherapy, regardless of platinum-sensitive recurrence or platinum-resistant recurrence, and providing more options for SCLC patients.

02

Conditions studied

  • Small Cell Lung Cancer (SCLC)
03

In context

Lung Neoplasms

7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.

This study's planned enrollment of 33 is below the median of 60 across 5,295 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

This is the only study on the registry with Haibo Zhang as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Subjects volunteered to participate in this study and signed the informed consent, with good compliance and follow-up;
  2. Male or female patients aged between 18 and 75 years;
  3. Patients with extensive small-cell lung cancer diagnosed by pathology, who have received first-line chemotherapy/PD-L1(CSCO rocommended standard therapy ) and failed treatment, and who have measurable target lesions; Definition of treatment failure: disease progression or intolerance during or after chemotherapy treatment for who have previously received concurrent chemoradiotherapy or adjuvant chemotherapy, if recurrence/metastasis occurs within 6 months after the end of the last treatment, the original treatment plan is defined as the subject's first-line treatment plan.
  4. The interval between the time of disease progression and the end of the last systemic chemotherapy was less than 6 months;
  5. Life expectancy of at least 3 months, ECOG score: 0-1;
  6. The main organs are functioning normally

Exclusion criteria

Exclusion criteria:

  1. Patients with previous use of anlotinib capsules or other antiangiogenic drugs;
  2. Previous use of tislelizumab injection other anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, as well as any other antibody or drug therapy targeting T cell co-stimulatory or checkpoint pathways, such as ICOs or agonists (such as CD40, CD137, GITR, Ox40, etc.);
  3. Patients who have previously used Irinotecan injection or other camptothecin drugs
  4. Patients who have received two or more platinum-containing two-drug chemotherapy (adjuvant chemotherapy relapse time within 6 months is counted as first-line chemotherapy);
  5. Imaging (CT or MRI) showed obvious pulmonary cavitary tumor;
  6. History and complications
  7. Unacceptable toxicity after prior anti-PD-L1 treatment is defined as follows:

A. Grade ≥ 3 AE associated with anti-PD-L1 therapy that does not respond to standard therapy and requires treatment termination.

B. Grade ≥ 2 imAE associated with anti-PD-L1 therapy, unless AE is restored or well controlled after discontinuation of anti-PD-L1 therapy and/or steroid therapy, except for prior colitis, encephalitis, myocarditis, hepatitis, uveitis, and lung inflammation.

C. Any grade of CNS or ocular AE associated with anti-PD -L1. Note: Patients with prior endocrine AE are allowed to be enrolled if they remain stable and asymptomatic after appropriate alternative therapy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    exploratory research

    Anlotinib 10mg QD with 2W stop 1W tiselizumab injection 200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W

    Drug: Anlotinib Tislelizumab Irinotecan

Interventions

  • DrugAnlotinib Tislelizumab Irinotecan

    Anlotinib 10mg QD 2W stop 1W Tislelizumab injection200mg Q3W Irinotecan (2 cycles) 100mg/m2,d1,d8,Q3W

06

What researchers measure

Primary outcomes

  1. ORR(Investigator-assessed)

    Tumor remission is revaluted by investigator according to RECIST v 1.1

    Time frame: up to 48months

Secondary outcomes

  1. Progression-free survival (PFS)

    The time from enrollment to (for any reason) progress disease

    Time frame: up to 48months

  2. overall survival (OS)

    The time from enrollment to (for any reason) death.

    Time frame: up to 48months

  3. (Disease control rate assessed by investigators) DCR (CR+PR+SD)

    The time from the first recorded objective tumor response (CR or PRorSD) to objective

    Time frame: up to 48months

  4. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Treatment-emergent adverse events is defined as any adverse events happened after randomization. The severity is validated using NCI-CTCAE V4.03.

    Time frame: Adverse events will be assessed during the period of 2cycles of treatment (21 days for each cycle), since the date of randomization. Adverse events will be recorded once any side effect happens.

07

Study locations

1 of 1 sites recruiting
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
    Guangzhou, Guangdong, China
    • Zhang Haibo · Contact
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05027100
Lead sponsor
Haibo Zhang
Responsible party
Haibo Zhang (Chief Physician, Guangzhou University of Traditional Chinese Medicine) — Sponsor-investigator
First posted
Aug 30, 2021
Start date
Sep 30, 2021
Primary completion
Dec 2022 (estimated)
Completion
Jun 2023 (estimated)
Last update
Jul 1, 2022

Study contacts

Yanjuan zhu, Dr
Contact
zyjsophy@gzucm.edu.cn
862081887233 ext. 3480
haibo zhang, Professor
principal investigator · Guangdong Provincial Hospital of Traditional Chinese Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion